Telix Pharmaceuticals (NASDAQ:TLX) Trading Down 4.3% – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price was down 4.3% during mid-day trading on Friday . The company traded as low as $11.75 and last traded at $11.8050. Approximately 19,705 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 197,524 shares. The stock had previously closed at $12.33.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Citigroup decreased their price target on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Stock Down 4.1%

The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business’s fifty day moving average is $10.67 and its 200-day moving average is $9.49.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in TLX. Rhumbline Advisers increased its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the period. XTX Topco Ltd purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at about $89,000. XY Capital Ltd acquired a new stake in Telix Pharmaceuticals during the first quarter worth about $120,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the second quarter worth about $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.